Abstract
Despite their relatively recent discovery in 1998, the hypocretins (also known as orexins) and their receptors are already the focus of several investigations as sites for therapeutic intervention in a number of endocrinological and neurological disorders. The rapidity with which the hypocretin system has been adopted as a high-interest target is mainly the result of an accumulation of compelling evidence from in vivo studies showing that the hypocretins regulate a number of aspects of physiology and behavior, especially those involved in sleep, arousal, and energy homeostasis. High-throughput screening efforts by a number of pharmaceutical companies have now identified novel small molecules that interact potently and specifically with the hypocretin receptors. Despite these considerable efforts, very little is known regarding the structures of the receptors, their endogenous ligands, the molecular basis of their interactions, or the signaling pathways they use. For example, no attempt has been made through receptor mutagenesis, or by any other means, to define the key interactions that occur between the receptors and the endogenous peptide ligands. Although such studies are likely to be ongoing within pharmaceutical companies with active hypocretin receptor drug discovery programs, the information available to the general scientific community remains very limited. This chapter reviews what is currently known about the molecular pharmacology of this system, focusing on the structures and activities of the peptides and some of the small molecules for which published biological data exist.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sakurai, T., Amemiya. A., Ishii, M., et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585.
de Lecea, L., Kilduff, T.S., Peyron, C., et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U S A 95, 322–327.
Dyer, C.J., Touchette, K.J., Carroll, J.A., Allee, G.L., and Matteri, R.L. (1999) Cloning of porcine prepro-orexin cDNA and effects of an intramuscular injection of synthetic porcine orexin-B on feed intake in young pigs. Domest. Anim. Endocrinol. 16, 145–148.
Ohkubo, T., Boswell, T., and Lumineau, S. (2002) Molecular cloning of chicken prepro-orexin cDNA and preferential expression in the chicken hypothalamus. Biochim. Biophys. Acta 1577, 476–480.
Voisin, T., Rouet-Benzineb, P., Reuter, N., and Laburthe, M. (2003) Orexins and their receptors: structural aspects and role in peripheral tissues. Cell. Mol. Life. Sci. 60, 72–87.
Okumura, T., Takeuchi, S., Motomura, W., et al. (2001) Requirement of intact disulfide bonds in orexin-A-induced stimulation of gastric acid secretion that is mediated by OX1 receptor activation. Biochem. Biophys. Res. Commun. 280, 976–981.
Zhu, Y., Miwa, Y., Yamanaka, A., et al. (2003) Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxinsensitive and-insensitive G-proteins. J. Pharmacol. Sci. 92, 259–266.
Malendowicz, L.K., Tortorella, C., and Nussdorfer, G.G. (1999) Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signaling cascade. J. Steroid Biochem. Mol. Biol. 70, 185–188.
Mazzocchi, G., Malendowicz, L.K., Gottardo, L., Aragona, F., and Nussdorfer, G.G. (2001) Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J. Clin. Endocrinol. Metab. 86, 778–782.
Nanmoku, T., Isobe, K., Sakurai, T., et al. (2000) Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells. Biochem. Biophys. Res. Commun. 274, 310–315.
Nanmoku, T., Isobe, K., Sakurai, T., et al. (2002) Effects of orexin on cultured porcine adrenal medullary and cortex cells. Regul. Pept. 104, 125–130.
Karteris, E., Randeva, H.S., Grammatopoulos, D.K., Jaffe, R.B., and Hillhouse, E.W. (2001) Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals. J. Clin. Endocrinol. Metab. 86, 4512–4519.
Lee, J.H., Bang, E., Chae, K.J., Kim, J.Y., Lee, D.W., and Lee, W. (1999) Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B. Eur. J. Biochem. 266, 831–839.
Monks, S.A., Karagianis, G., Howlett, G.J., and Norton, R.S. (1996) Solution structure of human neuropeptide Y. J. Biomol. NMR 8, 379–390.
Darker, J.G., Porter, R.A., Eggleston, D.S., et al. (2001) Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11, 737–740.
Asahi, S., Egashira, S., Matsuda, M., et al. (2003) Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg. Med. Chem. Lett. 13, 111–113.
Lang, M., Soll, R.M., Durrenberger, F., Dautzenberg, F.M., and Beck-Sickinger, A.G. (2004) Structure-activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. 47, 1153–1160.
Porter, R.A., Chan, W.N., Coulton, S., et al. (2001) 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11, 1907–1910.
Smart, D., Sabido-David, C., Brough, S.J., et al. (2001) SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132, 1179–1182.
Soffin, E.M., Evans, M.L., Gill, C.H., Harries, M.H., Benham, C.D., and Davies, C.H. (2002) SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. Neuropharmacology 42, 127–133.
Haynes, A.C., Jackson, B., Chapman, H., et al. (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul. Pept. 96, 45–51.
Rodgers, R.J., Halford, J.C., Nunes de Souza, R.L., et al. (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur. J. Neurosci. 13, 1444–1452.
Ishii, Y., Blundell, J.E., Halford, J.C., et al. (2004) Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol. Behav. 81, 129–140.
Duxon, M.S., Stretton, J., Starr, K., et al. (2001) Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement. Psychopharmacology (Berl.) 153, 203–209.
Kushikata, T., Hirota, K., Yoshida, H., et al. (2003) Orexinergic neurons and barbiturate anesthesia. Neuroscience 121, 855–863.
Haynes, A.C., Chapman, H., Taylor, C., et al. (2002) Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul. Pept. 104, 153–159.
Bingham, S., Davey, P.T., Babbs, A.J., et al. (2001) Orexin-A, a hypothalamic peptide with analgesic properties. Pain 92, 81–90.
Hirota, K., Kushikata, T., Kudo, M., Kudo, T., Smart, D., and Matsuki, A. (2003) Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats. Brain Res. 981, 143–150.
Langmead, C.J., Jerman, J.C., Brough, S.J., Scott, C., Porter, R.A., and Herdon, H.J. (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. 141, 340–346.
Hirose, M., Egashira, S., Goto, Y., et al. (2003) N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 13, 4497–4499.
McAtee, L.C., Sutton, S.W., Rudolph, D.A., et al. (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225–4229.
Aissaoui, H., Clozel, M., Weller, T., Koberstein, R., Sifferlen, T., and Fischli, W. Sulfonylaminoacetic acid derivatives. WO 2004/033418 A2. Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 2004.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Perry, S.J., Schwarz, D.A., Maki, R.A. (2006). Pharmacology of Hypocretin/Orexin Peptides and Small Molecules. In: Nishino, S., Sakurai, T. (eds) The Orexin/Hypocretin System. Contemporary Clinical Neuroscience. Humana Press. https://doi.org/10.1385/1-59259-950-8:349
Download citation
DOI: https://doi.org/10.1385/1-59259-950-8:349
Publisher Name: Humana Press
Print ISBN: 978-1-58829-444-9
Online ISBN: 978-1-59259-950-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)